NOMOPHOBIA, or NO MObile PHone Phobia, refers to a psychological condition in which people fear being disconnected from their mobile phones. The purpose of this review was to establish the prevalence of nomophobia symptoms in youth and young adults according to severity, country, culture, population, measurement tool, and year of data collection. An electronic search of fourteen databases, two digital preservation services, and three content aggregator services was conducted from the inception of each database until 15 September 2021. A total of 52 studies involving 47,399 participants from 20 countries were included in the analyses. The prevalence of nomophobia was defined as the proportion of individuals scoring at or above established cut-offs on validated measures. Based on a random-effects meta-analysis, approximately 20% of individuals showed mild symptoms of nomophobia, 50% showed moderate symptoms, and 20% showed severe symptoms. Our results showed that university students from non-Western cultures are the most likely to suffer severe symptoms. In the year 2021, the prevalence rate of nomophobia increased. The instrument that was best able to detect nomophobia was the nomophobia questionnaire. Most individuals who own mobile phones experience mild or moderate symptoms of nomophobia. Severe symptoms deserve attention from clinicians and research scientists. A valid method of identifying individuals with a severe addiction to their mobile phones will help with timely and effective therapeutic management.

Background: Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator widely used in patients with cystic fibrosis (CF), typically associated with mild, early onset liver enzyme elevations. Methods: We report a case of a 35-year-old man with CF who developed a marked hepatic transaminitis, with an alanine aminotransferase peaking at >1,000 IU/L after 30 months of stable ETI therapy. The patient was asymptomatic, and an extensive workup excluded viral, autoimmune, and metabolic liver disease. Various imaging modalities excluded other secondary causes, such as portal venous or arterial thromboses. Results: Using the Roussel Uclaf Causality Assessment Method (RUCAM), a score of 8 indicated a probable link to drug-induced liver injury (DILI), which was further supported by World Health Organization–Uppsala Monitoring Centre (WHO–UMC) causality assessment. Conclusions: This case highlights the potential for delayed-onset hepatotoxicity with ETI and emphasizes the need for continued liver monitoring during long-term therapy.

Background: Perineurioma is a rare benign peripheral nerve sheath tumor that can arise in various body locations. In the gastrointestinal (GI) tract, perineuriomas are uncommon and have only been reported in case reports and case series. In addition, a new classification suggests reclassifying benign fibroblastic polyps as perineurioma when they show positive markers of perineurial differentiation. Objective: This study aims to enhance understanding of GI tract perineuriomas by presenting a new case and conducting a systematic literature review. Methods: We described a new case of colonic perineurioma and systematically reviewed all case reports and case series on GI perineuriomas and benign fibroblastic polyps with perineurial markers. We searched ScienceDirect, PubMed/MEDLINE, and Web of Science up to May 2024. Results: A total of 148 cases were analyzed, and most of the cases were published in the last decade (2014–2024). The majority were females (59.46%), with a mean age of 51 years (standard deviation [SD] ±14.87). Most GI perineuriomas (87.5%) were in the distal colon, predominantly in the sigmoid/rectosigmoid (56%) and rectum (14%). Outside the colon, the stomach was the most affected site (7 of 10 cases), with fewer cases in the small intestine and esophagus. The two most commonly performed stains were for epithelial membrane antigen (EMA) and glucose transporter 1 (GLUT‐1), at 75% and 56% of cases, respectively. Noncolonic perineuriomas were generally larger and more symptomatic than colonic ones. Submucosal polyps were more likely symptomatic than mucosal polyps. Conclusion: Perineurioma in the GI tract is a rare benign polyp mainly identified in the distal colon. Its rarity and limited follow‐up data restrict our understanding of recurrence rates. We recommend reporting uncommon polyp locations, detailing polyp morphologies, and using at least two markers for classification.

Introduction: The mental health impact on relatives of cancer patients frequently goes unnoticed and is commonly undervalued. This study aimed to explore how personal factors such as the patient's degree of kin, marital status, cancer stage, and number of diagnosed family members are correlated with the severity of depression and anxiety among relatives of cancer patients. Method: This self-administered cross-sectional survey was conducted in Kuwait, employing a random sampling method to recruit participants. Depression and anxiety symptoms were assessed using the validated Arabic versions of the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) scale. Results: The mean age of the relatives of the cancer patients was 38.36 years (±13.44), with a female majority (59.72%). The prevalence of depression in the examined population was 60.1%, with the majority having mild depression (39.3%). On the other hand, the prevalence of anxiety in the same group was 51.2%, with the majority having mild disease (27.5%). Being female and having a cancer patient relative in the metastasis stage put patients’ relatives at a greater risk of depression and anxiety. Conclusion: The diagnosis of cancer necessitates mental health screenings for patients’ relatives, as findings from our study indicate that these individuals are at a high risk of developing depression and anxiety. Targeted support and referrals to specialists are crucial for mitigating the impact on their well-being.